Cargando…
Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness
BACKGROUND: Two new agents have recently been licensed for use in the treatment of metastatic renal cell carcinoma (RCC) in Europe. This paper aims to systematically review the evidence from all available randomised clinical trials of sunitinib and bevacizumab (in combination with interferon-α (IFN-...
Autores principales: | Thompson Coon, J S, Liu, Z, Hoyle, M, Rogers, G, Green, C, Moxham, T, Welch, K, Stein, K |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2720220/ https://www.ncbi.nlm.nih.gov/pubmed/19568242 http://dx.doi.org/10.1038/sj.bjc.6605167 |
Ejemplares similares
-
Reply: SUN vs BEVþIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival
por: Thompson Coon, J S, et al.
Publicado: (2010) -
Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib
por: Mickisch, G, et al.
Publicado: (2010) -
Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma
por: Hutson, T E, et al.
Publicado: (2014) -
Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
por: Feliu, J, et al.
Publicado: (2010) -
Buccodental side effects of sunitinib in patients with metastatic renal cell carcinoma
por: Gilabert, M, et al.
Publicado: (2013)